INVESTOR PRESENTATION - LIVING CELL TECHNOLOGIES LIMITED
LIVING CELL TECHNOLOGIES LIMITED
Health Care
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL for the treatment of type 1 diabetes and NTCELL , which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease. Former Names --
Read moreMarket Cap
9.14m
Price at Close
$0.016
4w avg. Volume
517.34k
4w avg. Turnover
$9.24k
Announcements
| announcement | t+2 movement | date |
|---|---|---|
| - | 18 Sep 2020 |
| -10.00% | 31 Aug 2020 |
| +12.50% | 21 Aug 2020 |
| 0.00% | 30 Jul 2020 |
| 0.00% | 30 Jul 2020 |
| +6.67% | 12 Jul 2020 |
| -7.14% | 08 Jul 2020 |
| -22.22% | 03 Jul 2020 |
| +21.43% | 29 Apr 2020 |
| -7.69% | 17 Apr 2020 |
Market Data
Current Price
$0.016
52WK HIGH
$0.024
52WK LOW
$0.009
1YR RETURN
-15.79%
1YR RETURN VS. SECTOR
-45.97%
90 DAY RETURN
+45.45%
ASX RANK
1,701
/2,019
SECTOR RANK
42
/47
SHARES OUTSTANDING
571.44m
LIVING CELL TECHNOLOGIES LIMITED
Health Care
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL for the treatment of type 1 diabetes and NTCELL , which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease. Former Names --
Read moreMarket Cap
9.14m
Price at Close
$0.016
4w avg. Volume
517.34k
4w avg. Turnover
$9.24k
ASX:LCT is not raising right now
Want to invest?
Contact Us
(03) 9028 2888
clients@freshequities.com
Address
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia